CC
BMRN icon

Centiva Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Centiva Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,000
Closed -$867K – 1730
2023
Q2 		$867K Buy
10,000
+5,000
+100% +$471K 0.02% 620
2023
Q1 		$486K Buy
+5,000
New +$518K 0.01% 852

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Centiva Capital's BMRN Position: Q3 2025 in Review

Centiva Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 13,795 shares — an estimated $758K sold.

Centiva Capital first reported a position in BMRN in Q4 2019 and held it in 15 quarters. The position peaked at $3.13M in Q1 2021. 577 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

  • Centiva Capital reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Centiva Capital sold 13,795 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $758K.
  • Centiva Capital first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 15 quarters.
  • Centiva Capital's BioMarin Pharmaceuticals position peaked at $3.13M in Q1 2021.
  • 577 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.